Key Highlights

  • Net loss for the third quarter narrowed 21% to USD 7.62 million, or USD 0.08 per share, from USD 9.69 million, or USD 0.10, in the third quarter of 2025.
  • Research and development expense fell 34% to USD 5.72 million, as CT-202 spending dropped 82% to USD 0.86 million while CTIM-76 spending rose 23% to USD 2.04 million.
  • Cash and cash equivalents were USD 34.4 million on September 30, 2026, which the company expects to fund operations to early in the fourth quarter of 2027.
  • The nine-month net loss widened 34% to USD 30.86 million, or USD 0.32 per share, and the accumulated Deficit stood at USD 161.8 million, according to the filing.

Third-Quarter Loss Narrows as CT-202 Spending Falls Away

Context Therapeutics (NASDAQ:CNTX) filed its Quarterly Report on November 10, 2026 for the three months ended September 30, 2026. The clinical-stage company develops T cell engager bispecific antibodies, which pair a tumor-targeting arm with an immune cell-activating arm, for solid tumors. Net loss was USD 7,623,706 against USD 9,693,237. Operating loss fell 25% to USD 7.96 million, and interest income dropped to USD 331,665 from USD 833,772 on lower cash balances. The drop in Research and Development reflected a USD 2.9 million decrease in contract Manufacturing for CT-202. General and administrative expense rose 19% to USD 2.24 million on personnel costs and termination benefits.

Portfolio Reset: CT-95 Out, CTIM-76 and CT-202 Move Forward

On August 5, 2026 the company announced a prioritization that ended internal development of CT-95, a mesothelin-targeting engager, and is winding down its Phase 1 trial. The filing says it does not expect material future costs there, and the third-quarter figures include estimated close-out costs of USD 1.54 million. CTIM-76, aimed at the CLDN6 protein, received FDA Fast Track Designation in April 2026 for platinum-resistant ovarian cancer. The company expects a Phase 1b expansion trial to begin in the first quarter of 2027 and initial data from every-three-week dosing in the second quarter of 2027. CT-202 dosed its first patient in September 2026, with first data expected in the second half of 2027.

Going Concern Doubt Sits Beside a USD 75 Million Funding Option

Cash and cash equivalents of USD 34.4 million are expected to last to early in the fourth quarter of 2027, yet the filing says there is substantial doubt about continuing as a Going Concern for 12 months from issuance. An at-the-market program allows sales of up to USD 75.0 million, all of it available at September 30, 2026. Using it would add shares and dilute holders. In May 2026 the company also amended its BioAtla license, paying USD 6.5 million in total, which ended future milestones and royalties to BioAtla. A Patent risk on CTIM-76 licensed technology remains, and the filing says defenses may not succeed.

Where Things Stand

To focus scarce cash, on the filing's account. Context Therapeutics (NASDAQ:CNTX) discontinued CT-95 and concentrated spending on CTIM-76 and CT-202, which helped cut third-quarter research and development by 34% and the net loss by 21%. The USD 34.4 million balance funds operations to early in the fourth quarter of 2027, but the nine-month loss is still higher and going concern doubt is formal. Next markers are the CTIM-76 Phase 1b start in the first quarter of 2027, its dosing update in the second quarter, CT-202 data in the second half and any use of the at-the-market program.